Development of selected reaction monitoring-MS methodology to measure peptide biomarkers in prostate cancer

Proteomics

Volumn 10, Issue 19, 2010, Pages 3506-3514

  Yocum, Anastasia K ^a,b   Khan, Amjad P ^a   Zhao, Rong ^a   Chinnaiyan, Arul M ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

AMACR; Biomedicine; EZH2; Prostate specific antigen; Selected reaction monitoring; Stable isotope dilution

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; BIOLOGICAL MARKER; PEPTIDE; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR EZH2;

ANALYTIC METHOD; ARTICLE; CELL LINE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE DILUTION ASSAY; MALE; MASS SPECTROMETRY; METHODOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; REPRODUCIBILITY; SELECTED REACTION MONITORING; SENSITIVITY AND SPECIFICITY;

CELL LINE, TUMOR; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 77957194214     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201000023     Document Type: Article

References (18)

1. Etzioni, R., Penson, D. F., Legler, J. M., di Tommaso, D. et al., Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J. Natl. Cancer Inst. 2002, 94, 981-990.
2. Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M. et al., Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N. Engl. J. Med. 2004, 350, 2239-2246.
3. Brawley, O. W., Ankerst, D. P., Thompson, I. M., Screening for prostate cancer. CA Cancer J. Clin. 2009, 59, 264-273.
4. Taylor, B. S., Pal, M., Yu, J., Laxman, B. et al., Humoral response profiling reveals pathways to prostate cancer progression. Mol. Cell. Proteomics 2008, 7, 600-611.
5. Keshishian, H., Addona, T., Burgess, M., Mani, D. R. et al., Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell. Proteomics 2009, 8, 2339-2349.
6. Kuhn, E., Addona, T., Keshishian, H., Burgess, M. et al., Developing multiplexed assays for troponin I and interleukin-33 in plasma by peptide immunoaffinity enrichment and targeted mass spectrometry. Clin. Chem. 2009, 55, 1108-1117.
7. Addona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J. et al., Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat. Biotechnol. 2009, 27, 633-641.
8. Anderson, N. L., Anderson, N. G., Pearson, T. W., Borchers, C. H. et al., A human proteome detection and quantitation project. Mol. Cell. Proteomics 2009, 8, 883-886.
9. Duncan, M. W., Yergey, A. L., Patterson, S. D., Quantifying proteins by mass spectrometry: the selectivity of SRM is only part of the problem. Proteomics 2009, 9, 1124-1127.
10. Cao, Q., Yu, J., Dhanasekaran, S. M., Kim, J. H. et al., Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 2008, 27, 7274-7284.
11. Kuefer, R., Varambally, S., Zhou, M., Lucas, P. C. et al., alpha-Methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am. J. Pathol. 2002, 161, 841-848.
12. Kumar-Sinha, C., Shah, R. B., Laxman, B., Tomlins, S. A. et al., Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. Am. J. Pathol. 2004, 164, 787-793.
13. Takahara, K., Azuma, H., Sakamoto, T., Kiyama, S. et al., Conversion of prostate cancer from hormone independency to dependency due to AMACR inhibition: involvement of increased AR expression and decreased IGF1 expression. Anticancer Res. 2009, 29, 2497-2505.
14. Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R. et al., The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419, 624-629.
15. Fortin, T., Salvador, A., Charrier, J. P., Lenz, C. et al., Clinical quantitation of prostate-specific antigen biomarker in the low nanogram/milliliter range by conventional bore liquid chromatography-tandem mass spectrometry (multiple reaction monitoring) coupling and correlation with ELISA tests. Mol. Cell. Proteomics 2009, 8, 1006-1015.
16. Sherman, J., McKay, M. J., Ashman, K., Molloy, M. P., How specific is my SRM? The issue of precursor and product ion redundancy. Proteomics 2009, 9, 1120-1123.
17. Sherman, J., McKay, M. J., Ashman, K., Molloy, M. P., Unique ion signature Mass Spectrometry: a deterministic method to assign peptide identity. Mol. Cell. Proteomics 2009, 8, 2051-2062.
18. Fortin, T., Salvador, A., Charrier, J. P., Lenz, C. et al., Multiple reaction monitoring cubed for protein quantification at the low nanogram/milliliter level in nondepleted human serum. Anal. Chem. 2009, 81, 9343-9352.